Equity Briefing : Pluristem's PLX cells may change bone marrow transplantation as well as other potential indications

CEO of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) (TASE:PLTR) tells shareholders that his firm's PLX cells may be effective in supporting bone marrow transplantation as well as other potential indications where bone marrow may be suppressed, such as radiation and chemotherapy. Additionally, work done in animals using PLX cells in Acute Radiation Sickness (ARS) provides another data point to approach that PLX cells can be administered  locally into skeletal muscle, distant to...

New York, 23/05/2012 (informazione.news - comunicati stampa - varie) CEO of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) (TASE:PLTR) tells shareholders that his firm's PLX cells may be effective in supporting bone marrow transplantation as well as other potential indications where bone marrow may be suppressed, such as radiation and chemotherapy.

Additionally, work done in animals using PLX cells in Acute Radiation Sickness (ARS) provides another data point to approach that PLX cells can be administered  locally into skeletal muscle, distant to the target organ, and obtain efficacious systemic effects.
Copyright Thomson Reuters


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: %s via Thomson Reuters ONE